Co-Diagnostics, Inc. (CODX)

Co-Diagnostics' stock has been impacted by several events in the past six months. The Q3 2025 earnings report showed a revenue decline, leading to a stock drop. The company closed a registered direct offering of common stock. Q2 2025 financial results also showed a revenue decline. Co-Diagnostics announced a reverse stock split. The company received a grant of an Australian patent and its JV CoSara received ISO 13485 certification and a CDSCO license. The stock price reached a new 52-week low and experienced a significant decline from the previous year.

Demand for Co-Diagnostics' products and services exhibits seasonality due to its focus on infectious diseases and vector-borne illnesses. Diseases like influenza have seasonal peaks, and the company's vector control products are impacted by mosquito seasons. The importance of surveillance against mosquito-borne pathogens is increasing.

Co-Diagnostics, Inc. is a molecular diagnostics company focused on developing, manufacturing, and marketing diagnostic technologies for the detection and analysis of nucleic acid molecules. Its core product is the Co-Dx PCR platform, a PCR testing system designed for point-of-care and at-home settings. The company offers PCR diagnostic tests for various infectious diseases and provides multiplexed tests for mosquito-borne diseases, molecular tools, liquid biopsy for cancer screening, and agricultural applications.

Co-Diagnostics operates in the United States and internationally, with a significant international presence through joint ventures. Its Indian joint venture, CoSara Diagnostics, has an established sales network and regulatory clearance for 15 infectious disease PCR tests. Co-Diagnostics is expanding its manufacturing capabilities in India and has formed CoMira Diagnostics with Arabian Eagle Manufacturing to commercialize Co-Dx technologies across Saudi Arabia and 18 other MENA nations. In the U.S., Co-Diagnostics has expanded its vector control footprint to 15 states.

Co-Diagnostics aims to democratize molecular diagnostics by making testing accessible globally and has engaged in market awareness activities. However, the company's reputation has faced challenges due to its financial performance, including missed revenue estimates and reliance on grant funding. On a positive note, Co-Diagnostics won the dismissal of a securities class action lawsuit.

Co-Diagnostics, Inc. has 37 institutional owners and shareholders holding a total of 5,748,193 shares. The largest block of ownership is held by retail/public investors, followed by insider ownership, and then institutional investors.